ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / RANI / financials
COYA (29) CRBP (34) LFVN (67) CING (34) ⌘ Pro Terminal β†’

Rani Therapeutics Holdings Inc. (Class A) (RANI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.55 -6.47% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.54

Rani Therapeutics Holdings Inc. (Class A) (RANI) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $76.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RANI Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is RANI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Rani Therapeutics Holdings Inc. (Class A) (NASDAQ: RANI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.55 (-6.47% 1D, market cap $76.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RANI ranks #802 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does RANI compare to COYA and CRBP in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RANI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, COYA (Coya Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $75.8M) and CRBP (Corbus Pharmaceuticals Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RANI?
β–Ό

Per RANI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001856725), Rani Therapeutics Holdings Inc. (Class A) generated $1.6M in revenue (+58.9% YoY), -$29.7M in net income, and -$18.8M in free cash flow against $58.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.54 (-1.35%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (30/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (5)Whales (7)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
$3 Bull$0 Base$0 Bear
πŸ“¬ FREE RANI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for RANI)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
πŸ” WHY RANI SCORES 30/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$0.67-9% Next Q
Q2 (-2Q)
35
Grade E$0.61+1.6% Next Q
Q3 (-1Q)
33
Grade E$0.62-11.3% Next Q
Current
30
Grade E$0.55-9.6% Hist 90D Ξ±
Trajectory: E (38) β†’ E (30)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a RANI Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While RANI currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.75) and Max Pain ($0.58) forces dealer call-delta covering toward $2.76.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RANIβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œRANI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How RANI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.6MGross Profit $849.2K (52%)Cost of Sales $783.8KOp Profit $0 (0%)OpEx (R&D/SG&A) $849.2KNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $185.1M
FY24
Rev $1.0M
FY25
Rev $1.6M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$1.6M52%-80%-$29.7M-$18.8M-45%
FY 2024$1.0M52%-80%-$30.0M-$35.8M-45%
FY 2023$185.1M52%-35.7%-$34.0M-$51.2M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RANI)

  • βœ“Walkthrough of RANI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
RANI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.50%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $0.59H $0.59L $0.55C $0.55VOL 415.9K
RES: $0.78SUP: $0.53SMA50: $0.75SMA200: $0.92
$1.26$1.06$0.87$0.68$0.49RES $0.78SUP $0.53$0.552026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RANI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ RANI Butterfly Map β†’ + Track RANI β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +58.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RANI today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for RANI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RANI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RANI)

Health Care Rank #802 of 1015 βš”οΈ COYA vs RANI Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (RANI vs. COYA, CRBP, LFVN, CING)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Rani Therapeutics Holdings Inc. (Class A) (RANI) ranks #802 by composite RQD confidence (30/100, grade E) and #683 by equity capitalization ($76.9M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with RANI at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RANI ACTIVE
Rani Therapeutics Holdings Inc. (Class A)
E 30/100 β€” β€” -35.0% -6.47% $76.9M Benchmark Subject
COYA
Coya Therapeutics Inc.
E 29/100 β€” β€” -35.0% -10.53% $75.8M /coya-vs-rani β†’
CRBP
Corbus Pharmaceuticals Holdings Inc.
E 34/100 β€” β€” -35.0% -7.23% $75.7M /crbp-vs-rani β†’
LFVN
Lifevantage Corporation (Delaware)
C+ 67/100 7.5x 80.4% 29.2% -0.17% $73.9M /lfvn-vs-rani β†’
CING
Cingulate Inc.
E 34/100 β€” β€” -35.0% +1.00% $73.1M /cing-vs-rani β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001856725 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rani Therapeutics Holdings Inc. (Class A) (RANI) reported GAAP revenue of $1.6M (+58.9% vs. FY2024 revenue of $1.0M , and -99.1% cumulative change since FY2023) , GAAP net income of -$29.7M, operating cash flow of -$18.7M, and free cash flow of -$18.8M (+47.4% YoY). On the balance sheet, RANI closed FY2025 with $58.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.6M -$29.7M -$18.7M -$18.8M $58.6M $0
FY2024 (FY) 2024-12-31 $1.0M -$30.0M -$35.5M -$35.8M $36.6M $9.6M
FY2023 (FY) 2023-12-31 $185.1M -$34.0M -$51.2M -$51.2M β€” β€”

3. RANI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RANI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rani Therapeutics Holdings Inc. (Class A) (NASDAQ: RANI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.55 (-6.47% 1D, market cap $76.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RANI ranks #802 in composite RQD confidence.

How does RANI compare to COYA and CRBP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RANI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, COYA (Coya Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $75.8M) and CRBP (Corbus Pharmaceuticals Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $75.7M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RANI?

Per RANI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001856725), Rani Therapeutics Holdings Inc. (Class A) generated $1.6M in revenue (+58.9% YoY), -$29.7M in net income, and -$18.8M in free cash flow against $58.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RANI trading relative to its 50-day, 200-day, and 52-week technical levels?

RANI last traded at $0.55 (-6.47% on volume of 415,915 shares), positioning the stock -26.67% below its 50-day simple moving average ($0.75) and -40.22% below its 200-day simple moving average ($0.92). Across its 52-week range of $0.55 to $2.63, RANI sits at the 0.0% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $0.62).

Direct Sub-Reports: RANI RQD Cockpit RANI 12M Forecast RANI Earnings & Move RANI Dividends & DRIP RANI Insiders & 13F RANI Whale Options RANI Profit Sankey RANI News & Why
ROARABLE RATING BRIEF β€’ RQD 30/100 (E) βœ“ SEC XBRL & RQD VERIFIED

RANI β€” Rani Therapeutics Holdings Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Rani Therapeutics Holdings Inc. (Class A) (RANI) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.55 (-6.47% 1D, market capitalization $76.9M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -22.28%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rani Therapeutics Holdings Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, gross margin is 0%, indicating no reported gross profit contribution. FY 2025 revenue was $1.6M against an operating loss of -$38.3M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Rani Therapeutics Holdings Inc. (Class A) (RANI) reported $1.6M in annual revenue (up from $1.0M in FY2024, +58.9% YoY) and -$29.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($185.1M revenue, -$34.0M net income) through FY2025, RANI scaled operating cash flow to -$18.7M and free cash flow to -$18.8M, backed by $58.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -22.28% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $0.55 – $2.63 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. A prospective investor should note that the absence of mapped links means the graph offers no evidence of supplier or customer concentration either way.

  • Key Question #1: Can RANI sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.6M and free cash flow of -$18.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RANI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RANI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rani Therapeutics Holdings Inc. (Class A) (RANI) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to RANI Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RANI Bull vs. Bear Conversation Board β€” What's Your Call at $0.55?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RANI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RANI:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $0.71 (+20.3%)
πŸ“Œ Pinned Debate

FDA acceptance into the Emerging Technology Program plus Chardan's Buy rating with a $6 target and $18.6M FY 2025 cash point to a possi

FDA acceptance into the Emerging Technology Program plus Chardan's Buy rating with a $6 target and $18.6M FY 2025 cash point to a possible catalyst-driven rerating from a $0.61 price.. When you look under the hood at RANI, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $2.63. My 12M target is $0.71.

ArenaChamp_24 πŸ‚ BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.50 (-15.3%)
Spot @ $0.59

An Altman Z-Score of 0.2, ROIC of -35%, and FCF yield of -22.28% indicate a distressed balance sheet and cash burn that could force fur

An Altman Z-Score of 0.2, ROIC of -35%, and FCF yield of -22.28% indicate a distressed balance sheet and cash burn that could force further dilution.. Look at the math on RANI: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.52 before getting long.

LIVE TAPE